TMEM33 Antibody, FITC conjugated
-
中文名稱：TMEM33兔多克隆抗體, FITC偶聯
-
貨號：CSB-PA023829LC01HU
-
規格：￥880
-
其他：
產品詳情
-
產品名稱：Rabbit anti-Homo sapiens (Human) TMEM33 Polyclonal antibody
-
Uniprot No.：
-
基因名：TMEM33
-
別名：TMEM33; DB83; Transmembrane protein 33; Protein DB83; SHINC-3
-
宿主：Rabbit
-
反應種屬：Human
-
免疫原：Recombinant Human Transmembrane protein 33 protein (177-247AA)
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：FITC
-
克隆類型：Polyclonal
-
抗體亞型：IgG
-
純化方式：>95%, Protein G purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
產品提供形式：Liquid
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：Acts as a regulator of the tubular endoplasmic reticulum (ER) network. Suppresses the RTN3/4-induced formation of the ER tubules. Positively regulates PERK-mediated and IRE1-mediated unfolded protein response signaling.
-
基因功能參考文獻：
- TMEM33 is a novel regulator of the PERK-eIE2alpha-ATF4 and IRE1-XBP1 axes of the UPR signaling. PMID: 26268696
-
亞細胞定位：Endoplasmic reticulum membrane; Multi-pass membrane protein. Melanosome. Nucleus envelope.
-
蛋白家族：PER33/POM33 family
-
組織特異性：Prostate cancer and several cancer cell lines (at protein level). Widely expressed. Expressed at higher levels in endocrine-resistant breast cancer cells as compared to endocrine-sensitive breast cancer cells. Expressed at higher levels in early recurrenc
-
數據庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
